Drug Trial Radar · NCT04486833
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
158
Planned (sponsor's estimate)
Start
Sep 3, 2021
Primary completion
Mar 2028
Study completion Mar 2029
Sponsor
- Lead sponsor
- Genprex, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this randomized study is to determine the safety and efficacy of quaratusugene ozeplasmid (Reqorsa) added to osimertinib in NSCLC patients with activating EGFR mutations who have progressed while on treatment with osimertinib. Quaratusugene ozeplasmid consists of non-viral lipid nanoparticles that encapsulate a DNA plasmid with the TUSC2 tumor suppressor gene and is the first systemic gene therapy for cancer. The study is comprised of a Phase 1 dose escalation portion and two Phase 2 portions evaluating safety and efficacy. Enrollment in the Phase 1 dose escalation portion is complete and the recommended Phase 2 dose (RP2D) was determined. Phase 2a has initiated and enrolled patients are treated with quaratusugene ozeplasmid at the RP2D in combination with osimertinib. In Phase 2b, patients will be randomized to receive either quaratusugene ozeplasmid plus osimertinib or platinum-based chemotherapy.
Conditions
- Carcinoma, Non-Small Cell Lung
Interventions
quaratusugene ozeplasmidBiological
Quaratusugene ozeplasmid is an experimental non-viral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.
osimertinibDrug
Osimertinib is a 3rd generation EGFR tyrosine kinase inhibitor (TKI) oral tablet administered daily, as indicated for treatment of patients with metastatic NSCLC whose tumors have EGFR genetic deletions or mutations.
Platinum-Based ChemotherapyDrug
Cisplatin and carboplatin are intravenously administered platinum agents that are combined with other cytotoxic chemotherapy agents such as pemetrexed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended Phase 2 Dose (RP2D) - Phase 1Time frame: First 21-day treatment cycle for each dose level cohort
- Overall Response Rate (ORR) - Phase 2aTime frame: Approximately 3 months
- Progression-free Survival (PFS) - Phase 2bTime frame: Approximately 11 months
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Valkyrie Clinical Trials
Los Angeles, California · Recruiting
Rocky Mountain Cancer Centers
Lone Tree, Colorado · Recruiting
Carle Cancer Institute
Urbana, Illinois · Recruiting
Markey Cancer Center
Lexington, Kentucky · Recruiting
Maryland Oncology Hematology
Rockville, Maryland · Terminated
The Valley Hospital - Luckow Pavilion
Paramus, New Jersey · Recruiting
Gabrail Cancer Center Research
Canton, Ohio · Recruiting
Millennium Oncology
Houston, Texas · Terminated
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Virginia Oncology Associates
Norfolk, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.